Hutchison China MediTech (HCM) announces the first commercial launch of fruquintinib capsules, or Elunate, with the initiation of product sales in China. Elunate is for the treatment of patients with metastatic colorectal cancer, or CRC, that have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan, including those who have previously received or are unsuitable for anti-vascular endothelial growth factor therapy and/or anti-epidermal growth factor receptor therapy. CRC is the second most common cancer type in China, with about 380,000 new cases per year. The market launch of Elunate in China is being conducted through collaboration with Chi-Med’s partner Eli Lilly (LLY).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.